新冠病毒药物研发应靶向病毒还是我们自身？——抗流感病毒疗法的经验教训
Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenza virus therapies.
作者信息
Liao Jiayu, Way George, Madahar Vipul
机构信息
Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.
出版信息
Med Drug Discov. 2020 Mar;5:100037. doi: 10.1016/j.medidd.2020.100037. Epub 2020 Apr 13.
Abstract
The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.
摘要
2019年12月新冠疫情被报道后，它具有高度传染性，目前已蔓延至190多个国家，造成了严重的公共卫生负担。目前，尚无疫苗或特定药物可治疗由新型冠状病毒SARS-CoV-2引起的新冠疫情。针对这一紧急情况，美国食品药品监督管理局（FDA）已批准瑞德西韦和羟氯喹作为紧急使用授权用于治疗新冠疫情。然而，即使在这场疫情之后，新冠疫情仍有可能卷土重来。因此，我们需要想出新的药物研发策略，以便在未来抗击新冠疫情。
相似文献
1
Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenza virus therapies.新冠病毒药物研发应靶向病毒还是我们自身？——抗流感病毒疗法的经验教训
Med Drug Discov. 2020 Mar;5:100037. doi: 10.1016/j.medidd.2020.100037. Epub 2020 Apr 13.
2
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay.基于荧光的高通量 SARS-CoV-2 3CL 报告酶测定法的建立。
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01265-20.
3
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.
4
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程：从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
5
Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.从单个细菌人工染色体中拯救 SARS-CoV-2。
mBio. 2020 Sep 25;11(5):e02168-20. doi: 10.1128/mBio.02168-20.
6
An update on novel COVID-19 pandemic: a battle between humans and virus.关于新型 COVID-19 大流行的最新情况：人类与病毒之间的战斗。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5819-5829. doi: 10.26355/eurrev_202005_21377.
7
FDA efficiency for approval process of COVID-19 therapeutics.美国食品药品监督管理局批准新冠治疗药物的流程效率
Infect Agent Cancer. 2020 Dec 1;15(1):73. doi: 10.1186/s13027-020-00338-z.
8
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer.天然产物单独或与美国食品药品监督管理局（FDA）批准的药物联合使用，用于治疗新冠肺炎和肺癌。
Biomedicines. 2021 Jun 18;9(6):689. doi: 10.3390/biomedicines9060689.
9
Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS.确定对抗COVID-19的新药物治疗方法：一种使用iLINCS的基于特征的方法。
Res Sq. 2020 Apr 30:rs.3.rs-25643. doi: 10.21203/rs.3.rs-25643/v1.
10
Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products.用于 COVID-19 的单克隆抗体疗法：经验教训及对未来产品开发的影响。
Curr Opin Biotechnol. 2022 Dec;78:102798. doi: 10.1016/j.copbio.2022.102798. Epub 2022 Sep 2.
引用本文的文献
1
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.严重急性呼吸综合征冠状病毒2的进化：对诊断、治疗、疫苗有效性及研发的影响
Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017.
2
Human Post-Translational SUMOylation Modification of SARS-CoV-2 Nucleocapsid Protein Enhances Its Interaction Affinity with Itself and Plays a Critical Role in Its Nuclear Translocation.人类 SARS-CoV-2 核衣壳蛋白翻译后 SUMOylation 修饰增强了其自身的相互作用亲和力，并在核易位中发挥关键作用。
Viruses. 2023 Jul 21;15(7):1600. doi: 10.3390/v15071600.
3
Human SUMOylation Pathway Is Critical for Influenza B Virus.人源 SUMOylation 通路对乙型流感病毒至关重要。
Viruses. 2022 Feb 3;14(2):314. doi: 10.3390/v14020314.
4
Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications.利用针对转录后修饰的单细胞RNA测序数据筛选可用于治疗SARS-CoV-2和流感败血症的可重新利用药物。
Precis Clin Med. 2021 Aug 28;4(4):215-230. doi: 10.1093/pcmedi/pbab022. eCollection 2021 Dec.
5
Mutual Pan-African support paradigm to produce scientific evidence of traditional medical practices for use against COVID-19 and emerging pandemics.泛非相互支持模式，以产生传统医学实践用于对抗COVID-19和新出现的大流行病的科学证据。
Sci Afr. 2021 Nov;14:e01046. doi: 10.1016/j.sciaf.2021.e01046. Epub 2021 Nov 16.
6
A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality.以病毒为中心与以患者为中心的治疗尝试降低 COVID-19 死亡率的比较。
Emerg Microbes Infect. 2021 Dec;10(1):2256-2263. doi: 10.1080/22221751.2021.2006579.
7
iDMer: an integrative and mechanism-driven response system for identifying compound interventions for sudden virus outbreak.iDMer：一种用于识别突发病毒爆发的化合物干预措施的综合和机制驱动的反应系统。
Brief Bioinform. 2021 Mar 22;22(2):976-987. doi: 10.1093/bib/bbaa341.
本文引用的文献
1
New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections.用于治疗流感病毒感染的应对病毒与宿主相互作用的新药物策略。
Eur J Pharmacol. 2017 Aug 15;809:178-190. doi: 10.1016/j.ejphar.2017.05.038. Epub 2017 May 19.
2
Antiviral therapies on the horizon for influenza.即将出现的流感抗病毒疗法。
Curr Opin Pharmacol. 2016 Oct;30:106-115. doi: 10.1016/j.coph.2016.08.003. Epub 2016 Aug 26.
3
Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing.2013年和2014年北京流感季期间患者流感病毒的耐药性及基因进化分析
Microb Drug Resist. 2017 Mar;23(2):253-260. doi: 10.1089/mdr.2015.0297. Epub 2016 May 20.
4
Nitazoxanide: a first-in-class broad-spectrum antiviral agent.硝唑尼特：一种一流的广谱抗病毒药物。
Antiviral Res. 2014 Oct;110:94-103. doi: 10.1016/j.antiviral.2014.07.014. Epub 2014 Aug 7.
5
Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2+) stores.硝唑尼特，一种抗病毒噻唑酰胺，可耗尽ATP敏感性细胞内钙储备。
Virology. 2014 Aug;462-463:135-48. doi: 10.1016/j.virol.2014.05.015. Epub 2014 Jun 25.
6
Systematic determinations of SUMOylation activation intermediates and dynamics by a sensitive and quantitative FRET assay.通过灵敏且定量的荧光共振能量转移分析对SUMO化激活中间体和动力学进行系统测定。
Mol Biosyst. 2012 Jun;8(6):1723-9. doi: 10.1039/c2mb05465e. Epub 2012 Mar 30.
7
Human pathogens and the host cell SUMOylation system.人体病原体与宿主细胞 SUMOylation 系统。
J Virol. 2012 Jan;86(2):642-54. doi: 10.1128/JVI.06227-11. Epub 2011 Nov 9.
8
Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity.冠状病毒：一种 RNA 校对机器调节复制保真度和多样性。
RNA Biol. 2011 Mar-Apr;8(2):270-9. doi: 10.4161/rna.8.2.15013. Epub 2011 Mar 1.
9
A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.日本山形县奥司他韦耐药性甲型 H1N1 流感病毒的两年监测及奥司他韦和扎那米韦的临床疗效。
Virol J. 2010 Mar 5;7:53. doi: 10.1186/1743-422X-7-53.
10
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.美国出现对奥司他韦耐药的甲型H1N1流感病毒感染情况。
JAMA. 2009 Mar 11;301(10):1034-41. doi: 10.1001/jama.2009.294. Epub 2009 Mar 2.
Zotero 插件